Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...

The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

DUBAI, UAE - Media OutReach Newswire - 28 January 2025 - AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...